ISB 2001, a first-in-class trispecific antibody developed by Ichnos Glenmark Innovation, showed a 79% response rate in relapsed/refractory multiple myeloma patients, with durable outcomes and a favourable safety profile. The results were shared at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025, one of the world’s largest cancer conferences.
